Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Taking the Road Less Traveled: Following Molecular Trail Markers.

Clinical cancer research : an official journal of the American Association for Cancer Research - 14 Oct 2022

Veneziani Ana C, Oza Amit M

Abstract excerpt

Targeted therapy largely remains an unmet therapeutic need for low-grade serous ovarian carcinomas. However, recent advances in molecular characterization are beginning to change the landscape. A recent article highlights the association of genetic alterations with clinical outcomes, widening the scope of novel targeted therapies. See related article by Manning-Geist et al., p. 4456.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystadenocarcinoma, Serous
Share to Mutation
Share to Ovarian Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Peritoneal Neoplasms

Source

Identifiers

PMID: 35960159
DOI: 10.1158/1078-0432.CCR-22-1623

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Taking the Road Less Traveled: Following Molecular Trail Markers.PMID 35960159Read ↗

Ovarian cancer: Novel molecular aspects for clinical assessmentSemantic proximity Read ↗

Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapiesSemantic proximity Read ↗

PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectationsSemantic proximity Read ↗

Better therapeutic trials in ovarian cancer.Semantic proximity Read ↗

Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.Semantic proximity Read ↗

Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening.Semantic proximity Read ↗

Improving outcomes in ovarian cancer: a work in progress.Semantic proximity Read ↗

Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.Semantic proximity Read ↗

Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targetsSemantic proximity Read ↗

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.Semantic proximity Read ↗

EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy.Semantic proximity Read ↗

Molecular profiling and commercial predication assays in ovarian cancer: still not ready for prime time?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.